Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Brantley P JarvisAugust F HoltynShrinidhi SubramaniamDavid Andrew TompkinsEmmanuel A OgaGeorge E BigelowKenneth SilvermanPublished in: Addiction (Abingdon, England) (2018)
Many individuals intending to start extended-release naltrexone (XR-NTX) do not and most who do start XR-NTX discontinue treatment prematurely, two factors that limit its clinical utility significantly. XR-NTX appears to decrease opioid use but there are few experimental demonstrations of this effect.
Keyphrases